Glycyx

Glycyx is at the forefront of cancer treatment by addressing the overlooked issue of opioids reducing immunotherapy effectiveness. As a biotech firm entering Phase 2, we are pioneering a novel therapy to ensure pain management doesn't compromise anti-PD1/PD-L1 treatments. Our goal: to greatly enhance survival and quality of life for cancer patients globally. The integration of opioids into cancer care, vital for managing the severe pain experienced by patients, inadvertently presents a significant challenge in oncological treatment effectiveness. Recent scientific insights reveal that opioids, beyond their analgesic properties, undermine the efficacy of immune checkpoint inhibitors (ICIs) — a cornerstone in modern cancer therapy known for their potential to significantly improve survival in various solid tumors. This interaction leads to what is identified as Opioid-Induced Immunotherapy Failure (OIIF), a condition where the immunosuppressive and pro-angiogenic effects of opioids diminish the body's immune response to cancer cells, thereby compromising the effectiveness of ICIs. Glycyx proposes a groundbreaking solution to this critical challenge with the development of a small molecule peripherally restricted opioid antagonist designed to counteract the negative effects of opioids on immune checkpoint inhibitor therapies without compromising pain relief. This novel drug, intended as a combination therapy with ICIs, axelopran will: • Reverse Opioid-Induced Immunosuppression • Enable Re-challenge in Treatment-Resistant Cancers • Robust Safety Credentials Established in Earlier Studies • Demonstrated Efficacy in Preclinical Studies • Phase 2 Ready, CMC Complete, Clinical Supply Built through Phase 3